Evidence suggesting that discontinuous dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors

Amit Dipak Amin, Soumya S. Rajan, Winnie S. Liang, Praechompoo Pongtornpipat, Matthew J. Groysman, Edgar O. Tapia, Tara L. Peters, Lori Cuyugan, Jonathan Adkins, Lisa M. Rimsza, Yves A. Lussier, Soham D. Puvvada, Jonathan H. Schatz

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Fingerprint Dive into the research topics of 'Evidence suggesting that discontinuous dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences